Developmental switches regulating tissue cyst formation
调节组织囊肿形成的发育开关
基本信息
- 批准号:9383727
- 负责人:
- 金额:$ 57.07万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2022-07-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdverse effectsAffectAgeAnimal ModelAnimalsAntigensBiochemicalBiologyBlindnessCell Culture TechniquesCell CycleCenters for Disease Control and Prevention (U.S.)ChronicChronic DiseaseClinicalComplexCystDNA Binding DomainDNA SequenceDevelopmentDiseaseDrug or chemical Tissue DistributionEnvironmentEquilibriumEye diseasesGene ExpressionGenesGeneticGenetic ModelsGenetic TranscriptionGrowthHealth HazardsImmune responseImmune systemIndividualInfectionInvestmentsKnock-outLeadLearningLifeLife Cycle StagesModelingMolecularMusNuclear ProteinOutcomeParasitesParasitic infectionPharmaceutical PreparationsPopulationProteinsPublic HealthRecruitment ActivityRecurrent diseaseReverse TranscriptionRiskRoleStressTertiary Protein StructureTestingTissuesToxoplasmaToxoplasma gondiiToxoplasmosisTranscription CoactivatorTranscription Repressor/CorepressorTreatment Failureasexualbrain tissuecombatdisorder preventionexperimental studyloss of functionneglectnovel strategiespathogenpreventtherapy developmenttranscription factortransmission process
项目摘要
Project Summary
Toxoplasma gondii infections continue to be a public health hazard for millions of individuals that contact this
pathogen annually. More than 50 million individuals in the US are chronically infected with Toxoplasma gondii
and thousands of healthy individuals develop eye disease due to this infection that can lead to permanent
vision loss. The Centers for Disease Control and Prevention considers Toxoplasma one of the five most
important neglected parasitic infections. Individuals can be reasonably treated (despite significant side effects)
if clinical toxoplasmosis is presented, however, there is a lack of drugs to treat or prevent the tissue cyst that is
responsible for long-term infections. This therapy failure leaves at-risk individuals who become infected
vulnerable to disease relapse throughout their lifetimes. Understanding the developmental mechanisms
responsible for tissue cyst formation are needed to develop therapies to combat life-long disease. The
Toxoplasma biology that underlies chronic disease is a reversible transformation of the asexual replicating
tachyzoite into the latent bradyzoite stage. This critical developmental transition is accompanied by significant
changes in gene expression controlled by poorly defined transcriptional mechanisms. Recent experiments of
our group have identified key cell cycle regulated and stress-induced Toxoplasma ApiAP2 factors that prevent
or activate bradyzoite gene expression. We hypothesize these discoveries reveal a transcriptional network
that directs the competing needs of tachyzoite growth against development of the dormant tissue cyst required
for parasite transmission. To understand how this transcriptional network operates, we propose two specific
aims: In Aim 1, the experimental focus will be ApiAP2 transcriptional repressors that are expressed in the
second half of the tachyzoite cell cycle whose mechanisms we will define at the molecular level and
characterize in cell culture and animal models of parasite development. In Aim 2, we will determine how the
stress-induced ApiAP2 repressors and activators compete to control bradyzoite gene expression and
determine how these mechanisms influence Toxoplasma development in the intermediate host.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Michael W White其他文献
Michael W White的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Michael W White', 18)}}的其他基金
Defining the cell and molecular basis of Toxoplasma recrudescence
定义弓形虫复发的细胞和分子基础
- 批准号:
10330031 - 财政年份:2021
- 资助金额:
$ 57.07万 - 项目类别:
Defining the cell and molecular basis of Toxoplasma recrudescence
定义弓形虫复发的细胞和分子基础
- 批准号:
10180280 - 财政年份:2021
- 资助金额:
$ 57.07万 - 项目类别:
Defining the cell and molecular basis of Toxoplasma recrudescence
定义弓形虫复发的细胞和分子基础
- 批准号:
10540764 - 财政年份:2021
- 资助金额:
$ 57.07万 - 项目类别:
Developmental switches regulating tissue cyst formation
调节组织囊肿形成的发育开关
- 批准号:
10217990 - 财政年份:2017
- 资助金额:
$ 57.07万 - 项目类别:
Developmental switches regulating tissue cyst formation
调节组织囊肿形成的发育开关
- 批准号:
9980272 - 财政年份:2017
- 资助金额:
$ 57.07万 - 项目类别:
Studies of DNA Licensing in Apicomplexa Parasites
顶复门寄生虫 DNA 许可的研究
- 批准号:
9196820 - 财政年份:2016
- 资助金额:
$ 57.07万 - 项目类别:
The AP2 factors required for Toxoplasma replication
弓形虫复制所需的 AP2 因子
- 批准号:
8265918 - 财政年份:2011
- 资助金额:
$ 57.07万 - 项目类别:
The AP2 factors required for Toxoplasma replication
弓形虫复制所需的 AP2 因子
- 批准号:
8811088 - 财政年份:2011
- 资助金额:
$ 57.07万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 57.07万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 57.07万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 57.07万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 57.07万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 57.07万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 57.07万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 57.07万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 57.07万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 57.07万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 57.07万 - 项目类别:
Studentship














{{item.name}}会员




